What does Artiva Biotherapeutics, Inc. do?
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and…
What is Artiva Biotherapeutics, Inc.'s P/E and P/B ratio?
Artiva Biotherapeutics, Inc. has a P/E ratio of -1.9 and a P/B ratio of 0.87.
What is Artiva Biotherapeutics, Inc.'s debt-to-equity ratio?
Artiva Biotherapeutics, Inc. has a debt-to-equity ratio of 0.03.
How much does Artiva Biotherapeutics, Inc. owe compared with what it owns?
Artiva Biotherapeutics, Inc. owes $0.06 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Artiva Biotherapeutics, Inc.'s Positivity rank?
Artiva Biotherapeutics, Inc. is ranked #2,019 of 6,774 companies globally and #546 of 4,000 in United States on PositoAI, with a Positivity Score of 22,004.
Does Artiva Biotherapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Artiva Biotherapeutics, Inc..
Where can I read the latest news about Artiva Biotherapeutics, Inc.?
Recent headlines about Artiva Biotherapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Artiva Biotherapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Artiva Biotherapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.